Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans
Overview
We wanted to test the hypotheses that methylprednisolone up regulates u-AQP-2 in fasting healthy humans
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single
- Study Primary Completion Date: February 2007
Interventions
- Drug: Methylprednisolone
Clinical Trial Outcome Measures
Primary Measures
- u-AQP-2
- FeNa+
Participating in This Clinical Trial
Inclusion Criteria
- (1) Genders; both mal and female – (2) Age; 18- 65 years old – (3) BMI; below 30 – (4) Females had to bee in oral contraceptive treatment Exclusion Criteria:
- (1) Clinical signs or history of disease in the heart, lungs, kidneys or endocrine organs – (2) Abnormal laboratory test (blood haemoglobin, white cell count, platelets, plasma sodium, plasma potassium, plasma creatinine, plasma albumin, plasma bilirubin, plasma alanine aminotransferase, plasma cholesterol and blood glucose) – (3) Albuminuria or glucosuria – (4) Cancer – (5) Arterial hypertension – (6) Alcohol abuse – (7) Use of tobacco – (8) Medical treatment, except oral contraceptives – (9) Pregnancy or breast feeding – (10) Medicine abuse – (11) Donation of blood less than 1 month before the study.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Regional Hospital Holstebro
- Overall Official(s)
- Erling B Pedersen, Professor, Study Chair, Holstebro Hospital, 7500 Holstebro, Denmark
- Thomas G Knudsen, MD, Principal Investigator, Holstebro Sygehus
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.